Global Immuno-Oncology Summit | May 18-19 2017 | Berlin Germany

The Halcyon Group is pleased to invite you to the “Global Immuno-Oncology Summit” scheduled on May 18-19, 2017 in Berlin, Germany.
This premier B2B event will bring together experts from all levels of the value chain to ensure maximum knowledge transfer and professional exchange; elaborate on the best practices within the Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine industry as well as academia to discuss, hear and learn about their experiences on latest trends on companion diagnostics (CDx) development, to network and enjoy excellent mix of case studies, interactive panel discussions, speed networking and workshops.
It is an honor and privilege to invite you to participate in this Summit. We look forward to welcoming you at the Summit in Berlin.
 
 
 
Key Practical Learning Points of the Summit:

– The latest trends of Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine development
– Partnering strategies to achieve successful commercialization of Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine
– Pharmaceutical and Diagnostics Companies Perspectives
– Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine development and pre-launch commercialization costs
– Finding the appropriate business models for Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine companies
– Introduction of a strategy that can improve the existing models

Who Should Attend?

CEOs, Vice-Presidents, Directors, Chief Medical Officers, Managers and Seniors Including:

– Director, Global Diagnostic
– Associate Director, Immuno-Oncology, companion diagnostics (CDx), Biomaker and Personalized Medicine
– Senior Director, Worldwide Regulatory Strategy
– Leader, Companion Diagnostic Development
– Senior Director, Biomarkers
– Senior Director, Regulatory Affairs
– Scientific Director, Medical Sciences
– Leader, Companion Diagnostic Development
– Senior Principal Scientist
– Biomarker & Experimental Medicine Leader
– Director Diagnostic & Experimental Pathology
– Head, Personalized Healthcare, Corporate Development & Ventures

From industries including:  Pharmaceutical, Biotechnology, Research Institutes, CD entities

For more details please contact Marketing Manager Claire Heidi (claire.heidi@halcyongroup.eu) cc. info@halcyongroup.eu